Week In Review: Junshi Signs $1.1 Billion Deal For US-Canada Rights To PD-1

Shanghai Junshi Bio out-licensed US-Canada rights for its anti-PD-1 antibody to Coherus Bio​ in an agreement worth up to $1.1 billion. Syapse closed a $68 million growth equity investment led by China's Ally Bridge Group
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.